HS135: Novel Activin & GDF Ligand Trap for the Treatment of Pulmonary Hypertension (PH)
G. Schang (Montreal, Canada), M. Poujol De Molliens (Montreal, Canada), J. Denis (Montreal, Canada), C. Chauvet (Montreal, Canada), E. Brûlé (Montreal, Canada), V. Ganesh (Montreal, Canada), J. Schoelermann (Montreal, Canada), G. Tremblay (Montreal, Canada), I. Tikhomirov (Montreal, Canada), M. O'Connor-Mccourt (Montreal, Canada)
Source: International Congress 2022 – Basic science in pulmonary hypertension
Session: Basic science in pulmonary hypertension
Session type: Thematic Poster
Number: 4146
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Schang (Montreal, Canada), M. Poujol De Molliens (Montreal, Canada), J. Denis (Montreal, Canada), C. Chauvet (Montreal, Canada), E. Brûlé (Montreal, Canada), V. Ganesh (Montreal, Canada), J. Schoelermann (Montreal, Canada), G. Tremblay (Montreal, Canada), I. Tikhomirov (Montreal, Canada), M. O'Connor-Mccourt (Montreal, Canada). HS135: Novel Activin & GDF Ligand Trap for the Treatment of Pulmonary Hypertension (PH). 4146
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|